Patent applications published 3 February 2010

Published: 10-Mar-2010
Patient Experience

Patent applications are taken from the weekly European Patents Bulletin


  • Treatment of movement disorders by a combined use of botulinum toxin and muscle stimulation
    Merz Pharma 2148641*

  • Highly charged microcapsules
    Aquea Scientific 2148643*

  • Pharmaceutical compsns of clopidogrel
    Wockhardt Research Centre; Ujjainkar, Amol; Balla Pattabhi, Srinivas; Khan, Abdul; Murali, Narayanan; Jain, Girish 2148655*

  • Stabilised pharmaceutical compsn containing pregabaline
    Ratiopharm 2148656*

  • Process for obtaining steroidal phosphate compounds
    Hovione Inter 2148657*

  • Improved vitamin D content uniformity in pharmaceutical dosage forms
    Procter and Gamble 2148658*

  • Low dose doxepin formulations
    Somaxon Pharmaceuticals 2148659*

  • Sustained release
    Diurnal 2148660*

  • Oral controlled release compsns comprising vitamin D compound and waxy carrier
    Cytochroma; Proventiv Therapeutics 2148661*

  • Pulmonary delivery of spherical insulin microparticles
    Baxter International; Baxter Healthcare 2148663*

  • Use of antivirals in the treatment of medical disorders
    The University of Birmingham 2148664*

  • Use of 4-(nitooxy)-butyl-(S)-(6-methoxy-2-naphthyl)-propanoate for treating pain and inflammation
    Nicox 2148665*

  • Fulvene and fulvalene analogues and their use in treating cancers
    Emory University 2148666*

  • Use of cyclohexanehexol derivatives in the treatment of ocular diseases
    Waratah Pharmaceuticals 2148667*

  • Tapentadol for treating pain from arthritis
    Gruenenthal 2148669*

  • Titration of tapentadol
    Gruenenthal 2148670*

  • Oxazolidinone for the treatment and prophylaxis of pulmonary hypertension
    Bayer Healthcare 2148672*

  • Cinnamide compsns for dementia
    Eisai R&D Management 2148673*

  • Combination of a 5HT7 receptor ligand and an opioid receptor ligand
    Laboratoires Del Dr Esteve 2148674*

  • Anti-cancer medicine both for diagnosing and treating cancer
    Youl Chon Chemical 2148675*

  • Use of sapacitabine to treat proliferative disease
    Cyclacel 2148676*

  • kinase inhibitors useful for the treatment of myeloproliferative diseases and other proliferative diseases
    Deciphera Pharmaceuticals 2148677*

  • Antiviral drugs for treatment or prevention of dengue infection
    Siga Technologies 2148678*

  • Tetrahydropyrido[4,3-D]pyrimidinone derivatives and methods of use thereof
    Schering 2148679*

  • Combination of progesterone-receptor antagonist together with non-steroidal antioestrogen for use in BRCA mediated diseases
    Bayer Schering Pharma Aktiengesellschaft 2148680*

  • Progesterone antagonist and selective progesterone modulator in the treatment of uterine bleeding
    PregLem 2148681*

  • Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in BRCA mediated diseases
    Bayer Schering Pharma Aktiengesellschaft 2148682*

  • Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
    Proventiv Therapeutics 2148683*

  • Method of treating vitamin D insufficiency and deficiency
    Cytochroma 2148684*

  • Methods and compounds for vitamin D therapy
    Cytochroma; Proventiv Therapeutics 2148685*

  • Novel active ingredient in cicatrization and use thereof
    Laboratoires Urgo 2148686*

  • Treatment of infections by carbon monoxide
    Alfama Investigacao e Desenvolvimento de Productos Farmaceuticos 2148688*

  • Compsns comprising an extract of Tiarella polyphylla or compounds isolated therefrom for preventing and treating cancer diseases
    Korea Research Institute of Bioscience and Biotechnology 2148689*

  • Compounds extracted from palm oil mill effluent for the treatment of cancer, compsns thereof and methods therewith
    Malaysian Palm Oil Board 2148690*

  • Local complement inhibition for treatment of complement-mediated disorders
    Potentia Pharmaceuticals 2148691*

  • Melanocortin receptor ligands modified with hydantoin
    Ipsen Pharma 2148692*

  • Alpha-1 antitrypsin having no significant protease inhibitor activity
    Regents of the University of Colorado 2148693*

  • Pharmaceutical agent for the treatment of fertility and gestation disorders, immunological diseases, and transplantation for use in veterinary medicine, particularly in horses, and methods for the production and treatment monitoring thereof
    Universitaet Leipzig 2148694*

  • Method and product for treatment and/or prevention of complications of prematurity
    Premacure 2148695*

  • Lyophilised antigen compsn
    GlaxoSmithKline Biologicals 2148697*

  • Microbial host-vector complementation system
    Nucleonics 2148698*

  • Vaccination regime for B-cell vaccines
    Cytus Biotechnology 2148699*

  • Pentamethine cyanine dyes carrying at least three sulphonic acid groups
    GE Healthcare 2148702*

  • Novel agent for salting out active principles in dressings containing at least one fatty substance
    Laboratoires Urgo 2148703*

  • Implant comprising a biotoxic coating, and method for the production thereof
    Fachhochschule Kiel 2148705*

  • Compsn for enhancing bone formation
    McGill University 2148708*

  • Injection device for delivering a medication
    Sanofi-Aventis Deutschland 2148710*

  • Pyrrolidione derivatives as dual NK1/NK3 receptor antagonists
    F Hoffmann-La Roche 2148857*

  • Inhibitors of IAP
    Genentech 2148858*

  • 5-lipoxygenase-activating protein (FLAP) inhibitors
    Amira Pharmaceuticals 2148859*

  • Chemicals, compsns and methods for treatment and prevention of orthopoxvirus infections and associated diseases
    Siga Technologies 2148860*

  • Aryl pyridyl sulphonamide derivatives, their manufacture and use as pharmaceutical agents
    F Hoffmann-La Roche 2148861*

  • Dihydroquinone and dihydronaphthridine inhibitors of JNK
    F Hoffmann-La Roche 2148862*

  • Phthalazine and isoquinoline derivatives with SLP receptor modulating activities
    Novartis 2148863*

  • Fused-ring heterocyclic opioids
    Rensselaer Polytechnic Institute 2148864*

  • Pyrazole inhibitors of WNT signalling
    Genentech; Curis 2148865*

  • Arylamide apyrimidone derivatives for the treatment of neurodegenerative diseases
    Sanofi-Aventis; Mitusbishi Tanabe Pharma 2148866*

  • Deuterated morpholinyl compounds
    Concert Pharmaceuticals 2148867*

  • Novel aromatic heterocyclic carboxylic acid amide derivatives useful as potassium channel modulators
    NeuroSearch 2148868*

  • Pyrimidinone derivatives and methods of use thereof
    Schering 2148869*

  • Pyrimidinone derivatives and methods of use thereof
    Schering 2148870*

  • Quinoline-carboxamide derivatives as P2Y12 antagonists
    Sanofi-Aventis 2148871*

  • Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists
    Janssen Pharmaceutica 2148872*

  • 4-alkoxypyridazine derivatives as fast-dissociating dopamine 2 receptor antagonists
    Janssen Pharmaceutica 2148873*

  • Pyrimidine derivatives and compsns as C-kit and PDGFR kinase inhibitors
    IRM LLC 2148874*

  • Compounds and compsns as C-kit and PDGFR kinase inhibitors
    IRM LLC 2148875*

  • Pyrazolone derivatives as PDE4 inhibitors
    Nycomed 2148876*

  • Inhibitors of hypoxia inducible factor (HIF) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
    Bayer Schering Pharma 2148877*

  • Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase
    Merck Frosst Canada 2148878*

  • Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
    Janssen Pharmaceutica 2148879*

  • P70 s6 kinase inhibitors
    Eli Lilly 2148880*

  • Fluorinated lanthanide probes for 19F magnetic resonance applications
    University of Durham 2148881*

  • Process for making topotecan
    Scinopharm Taiwan 2148882*

  • Process for the preparation of pure prulifloxacin
    Ranbaxy Laboratories 2148883*

  • Antibacterial 1,4,5-substituted aminoglycoside analogues
    Achaogen 2148884*

  • Tubulysine derivatives
    R&D Biopharmaceuticals 2148886*
    See more

You may also like

Digital

Pharma cybersecurity challenges: a holistic prescription

Read more
The pharmaceutical sector remains a prime target for cyberattacks. As an industry built on innovation, with extensive investments in research and development (R&D), intellectual property (IP) and patient information, it bridges the divide between business and healthcare, becoming a hotspot in the health data threat landscape

Trending Articles

  1. Pfizer wins battle over Viagra trademark Energy drinks brand Viaguara cannot be registered as an EU trademark
  2. Patent applications published 7 July 2010 Selected patent applications from the weekly European Patents Bulletin
  3. Genmab says GSK has settled patent case with Genentech Concerning two US patents for ofatumumbab
  4. Boehringer Ingelheim suffers Spiriva patent blow in India Indian patent office has revoked a patent granted for tiotropium bromide monohydrate under the Spiriva brand, paving the way for Cipla to continue selling its generic version in the Indian market
  5. Phillips-Medisize acquires mini-tablet dispenser patent The US company has acquired exclusive ownership of the patent from a global pharmaceutical company and expects to make the product available by early 2020

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Digital

Pharma cybersecurity challenges: a holistic prescription

The pharmaceutical sector remains a prime target for cyberattacks. As an industry built on innovation, with extensive investments in research and development (R&D), intellectual property (IP) and patient information, it bridges the divide between business and healthcare, becoming a hotspot in the health data threat landscape
Regulatory

Pharmaseal reaches milestone in crowdfunding campaign

The company was first founded in 2016
Patient Experience

Ilya Pharma awarded engineered lactic acid bacterial strain patent

The patent covers the use of engineered lactic acid bacterial strains for all human and animal wounds, not just skin
Pharmaceutical

A card in the competition for COVID-19 drug supply

The patent system has come under pressure both politically and, more recently, as pharma companies scale-up their operations to make large amounts of drugs available to treat COVID-19, reports Paul England, Senior Professional Support Lawyer at Taylor Wessing
Ingredients

Sigrid Therapeutics obtains US patent for silica-based biomaterial SiPore15 for the treatment and prevention of obesity

Mesoporous silica particles (MSP) are a type of ingestible synthetic amorphous silica particles that can be produced with a large surface area and a range of pore sizes
Ingredients

VistaGen and Nuformix agree to develop cocrystalline forms of AV-101

The drug for treatment of multiple CNS conditions will be reformed into a novel patentable form to potentially improve delivery and give more intellectual property protection
Digital

Documentation complexity at crisis point?

Do we focus too much on the paperwork, to the detriment of product and patients? Has documentation become so complex it’s become a dangerous distraction and your biggest risk? by Martin Lush
Subscribe now